New aspects of immunological risk factors in the treatment of recurrent pregnancy loss

Abstract

Recurrent Pregnancy Loss (RPL) is diagnosed in 3% of all patients of reproductive age and is of high interest to reproductive medicine specialists. Immunological predispositions are among the crucial risk factors for RPL development in female patients suffering from RPL. Therefore, the purpose of this work is to investigate the role and effectiveness of individualised immunological treatment approaches by analysing several clinical cases with diagnosed pregnancy loss and the results of tailored immunological therapies. Based on 25 years of clinical experience and scientific research the paper analysed the relationship between Human Leukocyte Antigens (HLA) tissue compatibility and ABO blood group system incompatibility in immunological pregnancy failure. The connection of these factors was shown in 2 clinical cases suffering from RPL who agreed to participate in research. Research was performed at Nakhchivan Birth Center and Nakhchivan State University. The results of the study provided evidence based on these cases of RPL that ended with successful childbirth after the suggested genetic assessment and immunological treatment. Individual treatment of immunological pregnancy failure with HLA and ABO blood group incompatibilities showed more effective outcomes if compared to previous schemes of treatment. HLA compatibility in loci 3 combined with affinity on the ABO system strongly demanded immunological therapy prescription for successful implantation of the blastocyst. The outcomes obtained from the study can be implemented in obstetrics and gynecology for the improvement of clinical cases suffering from RPL.